拉泽替尼联合培美曲塞卡铂用于拉泽替尼进展后EGFR突变晚期NSCLC
LUCAS II期单臂研究纳入86例拉泽替尼进展后EGFR突变晚期NSCLC患者,给予拉泽替尼240mg每日联合培美曲塞-卡铂4周期后维持治疗。81例可评估患者中位PFS为9.5个月(95%CI 6.3-9.6),中位OS为15.9个月(95%CI 12.4-20.0),ORR为36.0%,基线脑转移患者颅内PFS为9.9个月。
要点
- 拉泽替尼进展后继续拉泽替尼联合铂-培美曲塞获9.5个月中位PFS。
- 基线脑转移患者颅内PFS达9.9个月,孤立颅内进展少见。
- ≥3级不良事件69.8%,以血液学为主,无新安全信号。
核心结论
- 拉泽替尼进展后继续拉泽替尼联合铂-培美曲塞化疗显示有意义的全身和颅内活性,毒性可控。
- 需随机对照研究确证继续拉泽替尼的增量获益。
研究设计与样本
- 多中心、单臂、II期LUCAS研究(NCT05786430)。
- 纳入86例拉泽替尼进展后EGFR突变晚期NSCLC患者。
- 方案为拉泽替尼240mg每日联合培美曲塞-卡铂4周期,后维持拉泽替尼和培美曲塞。
- 主要终点为PFS;次要终点包括OS、ORR、颅内PFS、安全性和探索性ctDNA分析。
主要发现
- 81例可评估患者中位PFS为9.5个月(95%CI 6.3-9.6;单侧p=0.017,对照无效中位值6.0个月)。
- 安全性人群中位OS为15.9个月(95%CI 12.4-20.0),ORR为36.0%(95%CI 26.0-47.1)。
- 46.5%患者有脑转移史;36例基线影像学脑转移患者中位颅内PFS为9.9个月(95%CI 7.8-16.4),孤立颅内进展少见。
- 基线ctDNA检出EGFR扩增与更差生存相关。
- ≥3级不良事件发生率69.8%,以血液学为主,无新安全信号。
关键数值与推荐
- 中位PFS 9.5个月(95%CI 6.3-9.6),单侧p=0.017对比无效中位值6.0个月。
- 中位OS 15.9个月(95%CI 12.4-20.0)。
- ORR 36.0%(95%CI 26.0-47.1)。
- 基线脑转移患者中位颅内PFS 9.9个月(95%CI 7.8-16.4)。
- ≥3级不良事件69.8%。
临床怎么用
- 对于拉泽替尼进展后的EGFR突变晚期NSCLC患者,可考虑继续拉泽替尼联合铂-培美曲塞化疗。
- 该方案对基线脑转移患者显示颅内活性,孤立颅内进展少见。
- 治疗中需关注血液学毒性,≥3级不良事件发生率较高。
- 基线ctDNA检出EGFR扩增可能提示生存预后较差。
局限性
- 单臂II期研究,无随机对照,无法确证继续拉泽替尼的增量获益。
- 样本量有限(86例),结果需更大规模随机研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Therapeutic strategies after progression on third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) remain suboptimal in EGFR-mutant non-small cell lung cancer (NSCLC). We investigated whether continuing EGFR inhibition with lazertinib combined with platinum-pemetrexed chemotherapy could extend clinical benefit after progression on prior lazertinib. METHODS: In the multicenter, single-arm, phase II LUCAS study (NCT05786430), patients with advanced EGFR-mutant NSCLC who had progressed on lazertinib received lazertinib 240 mg daily plus pemetrexed-carboplatin for four cycles, followed by maintenance lazertinib and pemetrexed. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR), intracranial PFS, safety, and exploratory ctDNA analyses. RESULTS: Of 86 patients, 46.5% had a history of brain metastases. Among 81 response-evaluable patients, median PFS was 9.5 months (95% CI: 6.3-9.6; one-sided p = 0.017 against a null median of 6.0 months). In the safety population, median OS was 15.9 months (95% CI: 12.4-20.0) and ORR was 36.0% (95% CI: 26.0-47.1). Outcomes were similar irrespective of prior lazertinib line or EGFR subtype. Baseline ctDNA-detected EGFR amplification was associated with inferior survival. Among 36 patients with radiologically evident baseline brain metastases, median intracranial PFS was 9.9 months (95% CI: 7.8-16.4) with infrequent isolated intracranial progression. Grade ≥ 3 adverse events occurred in 69.8%, predominantly hematologic, without new safety signals. CONCLUSIONS: Continuation of lazertinib with platinum-pemetrexed chemotherapy after progression on prior lazertinib was associated with meaningful systemic and intracranial activity and manageable toxicity. Randomized evaluation is required to establish the incremental benefit of lazertinib continuation.
引用
- Hong MH, Shim BY, Kim CG, et al. Lazertinib plus pemetrexed and carboplatin in patients with EGFR-mutant advanced non-small cell lung cancer after progression on lazertinib. Eur J Cancer. 2026. PMID: 42887461. doi:10.1016/j.ejca.2026.117774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。